Company name: Moleculin LLC.
Industry: pharmaceuticals.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Location: Houston, Texas.
Solution/product: The stealth-mode company, which is based on technology developed at the MD Anderson Cancer Center, is listed on the center’s Office of Technology Commercialization’s website as a “specialty pharmaceutical company focused on preclinical and clinical development of cancer therapeutics.” However, on her public LinkedIn page, chief financial officer Lori Bisson writes that the early stage company is developing a number of compounds focused on proliferative skin disease. Records from an online patent database indicate that the company is working with caffeic acid compounds.
Money raised: nearly all of a $3.3 million equity round from 64 investors, according to a regulatory filing. In an equity round last year, the company raised at least $4.5 million.
Investors: unknown.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Management team: Chairman Walter Klempp is president and CEO of Tyrell Inc., which developed an at-home acne treatment device called Zeno. CEO Don Picker is also CEO at Intertech Bio and Sinapis Pharma, according to his LinkedIn profile.
Market size: Sales of dermatological drugs comprise a $25 billion market in the U.S., according to research firm Visiongain.
Competitors: Key players in the dermatological drug market include Genentech, GlaxoSmithKline, Johnson & Johnson, Medicis, Merck, Novartis, Roche and Valeant Pharmaceuticals.
